Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
Recruiting
Instituto Grifols, S.A.
Phase 3
2018-07-24
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label
clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20%
administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The
study population will consist of subjects being discharged after hospitalization for acute
decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring
diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or
during hospitalization but without ACLF at discharge.
Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
Recruiting
Grifols Therapeutics LLC
Phase 3
2018-07-24
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label
clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20%
administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The
study population will consist of subjects being discharged after hospitalization for acute
decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring
diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or
during hospitalization but without ACLF at discharge.
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
Recruiting
Institut d'Investigació Biomèdica de Bellvitge
Phase 3
2019-10-31
Community-acquired pneumonia (CAP) remains a leading cause of death world-wide.
Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration
would have a beneficial effect in outcome in patients with CAP remains uncertain.
This project proposes to test the hypothesis of whether the administration of albumin in
hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients
at day 5.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
